Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice
出版年份 2020 全文链接
标题
Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice
作者
关键词
-
出版物
JOURNAL OF CLINICAL INVESTIGATION
Volume 131, Issue 4, Pages -
出版商
American Society for Clinical Investigation
发表日期
2020-12-18
DOI
10.1172/jci139542
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Synthetic high-density lipoprotein nanodiscs for personalized immunotherapy against gliomas
- (2020) Lindsay Scheetz et al. CLINICAL CANCER RESEARCH
- The Misclassification of Diffuse Gliomas: Rates and Outcomes
- (2019) J. Bryan Iorgulescu et al. CLINICAL CANCER RESEARCH
- The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma
- (2019) Erik Ladomersky et al. Frontiers in Pharmacology
- IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response
- (2019) Felipe J. Núñez et al. Science Translational Medicine
- Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
- (2019) Danielle Golub et al. Frontiers in Oncology
- Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens
- (2019) Bas Weenink et al. Scientific Reports
- IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
- (2018) Erik Ladomersky et al. CLINICAL CANCER RESEARCH
- Current state and future prospects of immunotherapy for glioma
- (2018) Neha Kamran et al. Immunotherapy
- Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
- (2018) Lukas Bunse et al. NATURE MEDICINE
- Temozolomide for immunomodulation in the treatment of glioblastoma
- (2018) Aida Karachi et al. NEURO-ONCOLOGY
- Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
- (2018) Janeta Popovici-Muller et al. ACS Medicinal Chemistry Letters
- The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
- (2018) Luyan Mu et al. Frontiers in Molecular Neuroscience
- Harnessing the immune system in glioblastoma
- (2018) Nicholas F. Brown et al. BRITISH JOURNAL OF CANCER
- Infiltrative and drug‐resistant slow‐cycling cells support metabolic heterogeneity in glioblastoma
- (2018) Lan B Hoang‐Minh et al. EMBO JOURNAL
- Mutant IDH1 regulates the tumor-associated immune system in gliomas
- (2017) Nduka M. Amankulor et al. GENES & DEVELOPMENT
- Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas
- (2017) Gary Kohanbash et al. JOURNAL OF CLINICAL INVESTIGATION
- Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
- (2017) A Chaturvedi et al. LEUKEMIA
- Immunosuppressive Myeloid Cells’ Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy
- (2017) Neha Kamran et al. MOLECULAR THERAPY
- Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays
- (2017) Daniel J. Urban et al. Scientific Reports
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve
- (2016) Michael I Koukourakis et al. BRITISH JOURNAL OF CANCER
- Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
- (2016) Michele Ceccarelli et al. CELL
- Emerging immunotherapies for glioblastoma
- (2016) Rupen Desai et al. EXPERT OPINION ON EMERGING DRUGS
- IDH mutation is associated with higher risk of malignant transformation in low-grade glioma
- (2016) Severina Leu et al. JOURNAL OF NEURO-ONCOLOGY
- Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
- (2016) D. Mathios et al. Science Translational Medicine
- ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma
- (2016) Carl Koschmann et al. Science Translational Medicine
- Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion
- (2015) Kensuke Tateishi et al. CANCER CELL
- IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy
- (2015) K. Pilipow et al. CANCER RESEARCH
- 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling
- (2015) Xudong Fu et al. Cell Metabolism
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- New insights into IL-12-mediated tumor suppression
- (2014) S Tugues et al. CELL DEATH AND DIFFERENTIATION
- Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
- (2014) M. Candolfi et al. CLINICAL CANCER RESEARCH
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Blockade of mTOR Signaling via Rapamycin Combined with Immunotherapy Augments Antiglioma Cytotoxic and Memory T-Cell Functions
- (2014) Y. Mineharu et al. MOLECULAR CANCER THERAPEUTICS
- Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling
- (2013) A Ko et al. CELL DEATH AND DIFFERENTIATION
- What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
- (2013) J.-A. Losman et al. GENES & DEVELOPMENT
- An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
- (2013) D. Rohle et al. SCIENCE
- Strange attractors: DAMPs and autophagy link tumor cell death and immunity
- (2013) W Hou et al. Cell Death & Disease
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
- (2012) Sevin Turcan et al. NATURE
- Monoclonal antibody blockade of IL-2 receptor during lymphopenia selectively depletes regulatory T cells in mice and humans
- (2011) D. A. Mitchell et al. BLOOD
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
- (2011) Rasheduzzaman Chowdhury et al. EMBO REPORTS
- Recent advancements in multimodality treatment of gliomas
- (2011) Mersiha Hadziahmetovic et al. Future Oncology
- Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme
- (2011) C. E. Fadul et al. NEURO-ONCOLOGY
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- Immunological Factors Relating to the Antitumor Effect of Temozolomide Chemoimmunotherapy in a Murine Glioma Model
- (2009) T.-G. Kim et al. Clinical and Vaccine Immunology
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression
- (2009) James F Curtin et al. PLOS MEDICINE
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now